149 related articles for article (PubMed ID: 15479218)
1. Role of early insulin secretion in postglucose-loading hyperglycaemia and postfat-loading hyperlipidaemia: comparing nateglinide and glibenclamide for acute effects on insulin secretion in OLETF rats.
Mori Y; Kitahara Y; Miura K; Mine T; Tajima N
Diabetes Obes Metab; 2004 Nov; 6(6):422-31. PubMed ID: 15479218
[TBL] [Abstract][Full Text] [Related]
2. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes.
Vakkilainen J; Mero N; Schweizer A; Foley JE; Taskinen MR
Diabetes Metab Res Rev; 2002; 18(6):484-90. PubMed ID: 12469362
[TBL] [Abstract][Full Text] [Related]
3. Nateglinide suppresses postprandial hypertriglyceridemia in Zucker fatty rats and Goto-Kakizaki rats: comparison with voglibose and glibenclamide.
Mine T; Miura K; Kitahara Y; Okano A; Kawamori R
Biol Pharm Bull; 2002 Nov; 25(11):1412-6. PubMed ID: 12419950
[TBL] [Abstract][Full Text] [Related]
4. Improvement of glucose tolerance by nateglinide occurs through enhancement of early phase insulin secretion.
Uto Y; Teno S; Iwamoto Y; Omori Y; Takizawa T
Metabolism; 2002 Jan; 51(1):20-4. PubMed ID: 11782867
[TBL] [Abstract][Full Text] [Related]
5. Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166.
Kikuchi M
Diabet Med; 1996 Sep; 13(9 Suppl 6):S151-5. PubMed ID: 8894500
[TBL] [Abstract][Full Text] [Related]
6. Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine], on postprandial blood glucose excursion: comparison with voglibose and glibenclamide.
Ikenoue T; Okazaki K; Fujitani S; Tsuchiya Y; Akiyoshi M; Maki T; Kondo N
Biol Pharm Bull; 1997 Apr; 20(4):354-9. PubMed ID: 9145209
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics, insulinotropic action and hypoglycemic effect of nateglinide and glibenclamide in normal and diabetic rats.
Courtois P; Jijakli H; Ladriere L; Oguzhan B; Sener A; Malaisse WJ
Int J Mol Med; 2003 Jan; 11(1):105-9. PubMed ID: 12469228
[TBL] [Abstract][Full Text] [Related]
8. Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus.
Kahn SE; Montgomery B; Howell W; Ligueros-Saylan M; Hsu CH; Devineni D; McLeod JF; Horowitz A; Foley JE
J Clin Endocrinol Metab; 2001 Dec; 86(12):5824-9. PubMed ID: 11739446
[TBL] [Abstract][Full Text] [Related]
9. Long-term effects of glibenclamide and nateglinide upon pancreatic islet function in normal and diabetic rats.
Laghmich A; Ladrière L; Malaisse-Lagae F; Malaisse WJ
Pharmacol Res; 1999 Dec; 40(6):475-82. PubMed ID: 10660944
[TBL] [Abstract][Full Text] [Related]
10. Decreased blood glucose excursion by nateglinide ameliorated neuropathic changes in Goto-Kakizaki rats, an animal model of non-obese type 2 diabetes.
Kitahara Y; Miura K; Takesue K; Mine T; Wada R; Uchida Y; Ito S; Yagihashi S
Metabolism; 2002 Nov; 51(11):1452-7. PubMed ID: 12404197
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of lipoprotein lipase gene in tissues of the rat model with visceral obesity and postprandial hyperlipidemia.
Hikita M; Bujo H; Yamazaki K; Taira K; Takahashi K; Kobayashi J; Saito Y
Biochem Biophys Res Commun; 2000 Oct; 277(2):423-9. PubMed ID: 11032739
[TBL] [Abstract][Full Text] [Related]
12. Possibility of ideal blood glucose control by a new oral hypoglycemic agent, N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166), and its stimulatory effect on insulin secretion in animals.
Sato Y; Nishikawa M; Shinkai H; Sukegawa E
Diabetes Res Clin Pract; 1991 Apr; 12(1):53-9. PubMed ID: 1906797
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of glimepiride and glibenclamide on adipose tissue tumour necrosis factor-alpha mRNA expression and cellularity.
Mori Y; Komiya H; Kurokawa N; Tajima N
Diabetes Obes Metab; 2004 Jan; 6(1):28-34. PubMed ID: 14686960
[TBL] [Abstract][Full Text] [Related]
14. A placebo-controlled crossover study comparing the effects of nateglinide and glibenclamide on postprandial hyperglycaemia and hyperinsulinaemia in patients with type 2 diabetes.
Barnett AH; Anderson DM; Shelley S; Morgan R; Owens DR
Diabetes Obes Metab; 2004 Mar; 6(2):104-13. PubMed ID: 14746575
[TBL] [Abstract][Full Text] [Related]
15. Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166).
Gribble FM; Manley SE; Levy JC
Diabetes Care; 2001 Jul; 24(7):1221-5. PubMed ID: 11423506
[TBL] [Abstract][Full Text] [Related]
16. Control of postprandial hyperglycemia: optimal use of short-acting insulin secretagogues.
Carroll MF; Izard A; Riboni K; Burge MR; Schade DS
Diabetes Care; 2002 Dec; 25(12):2147-52. PubMed ID: 12453952
[TBL] [Abstract][Full Text] [Related]
17. Early insulin release effectively improves glucose tolerance: studies in two rodent models of type 2 diabetes mellitus.
de Souza CJ; Gagen K; Chen W; Dragonas N
Diabetes Obes Metab; 2001 Apr; 3(2):85-95. PubMed ID: 11298730
[TBL] [Abstract][Full Text] [Related]
18. Increased intestinal glucose absorption and postprandial hyperglycaemia at the early step of glucose intolerance in Otsuka Long-Evans Tokushima Fatty rats.
Fujita Y; Kojima H; Hidaka H; Fujimiya M; Kashiwagi A; Kikkawa R
Diabetologia; 1998 Dec; 41(12):1459-66. PubMed ID: 9867213
[TBL] [Abstract][Full Text] [Related]
19. The effects of nateglinide following oral glucose load in impaired glucose tolerance subjects: rapid insulin stimulation by nateglinide in IGT subjects.
Hirose T; Mizuno R; Yoshimoto T
Endocr J; 2002 Dec; 49(6):649-52. PubMed ID: 12625415
[TBL] [Abstract][Full Text] [Related]
20. Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine (A-4166).
Ikenoue T; Akiyoshi M; Fujitani S; Okazaki K; Kondo N; Maki T
Br J Pharmacol; 1997 Jan; 120(1):137-45. PubMed ID: 9117089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
